Millennium Management’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-20,197
Closed -$959K 5970
2025
Q3
$959K Sell
20,197
-294,792
-94% -$14.3M ﹤0.01% 4661
2025
Q2
$16.8M Buy
314,989
+84,125
+36% +$3.82M 0.01% 1754
2025
Q1
$9.35M Buy
230,864
+214,128
+1,279% +$9.08M 0.01% 2263
2024
Q4
$466K Sell
16,736
-57,892
-78% -$1.75M ﹤0.01% 4801
2024
Q3
$2.14M Sell
74,628
-94,963
-56% -$2.48M ﹤0.01% 3643
2024
Q2
$3.98M Sell
169,591
-622,984
-79% -$13.3M ﹤0.01% 2927
2024
Q1
$20M Buy
792,575
+535,381
+208% +$12.9M 0.01% 1556
2023
Q4
$6.01M Buy
+257,194
New +$5.07M ﹤0.01% 2631
2023
Q3
Sell
-4,884
Closed -$227K 6070
2023
Q2
$228K Sell
4,884
-5,282
-52% -$242K ﹤0.01% 5048
2023
Q1
$389K Sell
10,166
-236,851
-96% -$10.6M ﹤0.01% 4745
2022
Q4
$13.5M Buy
+247,017
New +$10.6M 0.01% 1821
2022
Q3
Sell
-520,769
Closed -$4.92M 7024
2022
Q2
$4.92M Buy
520,769
+455,525
+698% +$4.75M ﹤0.01% 2830
2022
Q1
$926K Buy
65,244
+45,501
+230% +$797K ﹤0.01% 4610
2021
Q4
$418K Buy
+19,743
New +$438K ﹤0.01% 5229
2021
Q2
Sell
-85,492
Closed -$2.48M 6467
2021
Q1
$2.48M Sell
85,492
-178,919
-68% -$5.42M ﹤0.01% 3328
2020
Q4
$6.82M Buy
264,411
+108,097
+69% +$3.01M ﹤0.01% 2147
2020
Q3
$4.81K Buy
156,314
+26,749
+21% +$935K 0.01% 1881
2020
Q2
$3.23M Buy
129,565
+65,026
+101% +$1.49M ﹤0.01% 2152
2020
Q1
$1.37M Buy
+64,539
New +$1.38M ﹤0.01% 2272
2019
Q4
Sell
-73,621
Closed -$1.67M 4160
2019
Q3
$1.67M Sell
73,621
-94,125
-56% -$2.19M ﹤0.01% 2555
2019
Q2
$3.21M Buy
+167,746
New +$3.18M ﹤0.01% 2106

Other funds holding AKRO

Millennium Management's AKRO Position: Q4 2025 in Review

Millennium Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,197 shares — an estimated $959K sold.

Millennium Management first reported a position in AKRO in Q2 2019 and held it in 21 quarters. The position peaked at $20M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Millennium Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Millennium Management sold 20,197 Akero Therapeutics shares in Q4 2025, an estimated $959K.
  • Millennium Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 21 quarters.
  • Millennium Management's Akero Therapeutics position peaked at $20M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.